5Craig WA, Kiem S, Jones R, et al. Impact of ESBLs on in vivo of four cephalosporins in the neutropenic mouse-thigh infection model, abstr. #A-1318. In: Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago:ICAAC, 2003, 14-17.
6Paterson DL, Ko WC,Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol, 2001, 39, 2206-2212.
7Jacoby GA, Munoz-Price S. The new beta-Lactamases. N Engl J Med, 2005,352: 380-391.
8Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes Antimicrob Agents Chemother, 2004, 48:1-14.
9Poirel L , Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolyzing extended-spectrum b-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother, 2002, 50: 1031-1034.
10Wang H, Kelk S, Wu WY, et al. Study of clinical isolates of Enterobacteriaceae producing extended-spectrum beta-lactamases: prevalence of CTX-M-3 at a hospital in China. Antimicrob Agents Chemother, 2003, 47: 790-793.
二级参考文献36
1Livermore DM, Williams JD. β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, eds. Antibiotics in laboratory medicine. 4th ed. Baltimore:Williams & Wilkins, 1996. 502-578.
2Sanders CC. β-lactamase of gram negative bacteria: new challenges for new drugs. Clin Infect Dis, 1992,14:1089-1099.
3Naumiuk L, Samet A, Dziemaszkiewicz E. Cefepime in vitro activity against derepressed extended-spectrum β-lactamase(ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J Antimicrob Chemother, 2001,48:321-322.
4National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 9th informational supplement(M100-S9). Wayne:NCCLS,1999.
5Coudron PE,Moland ES, Thomson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli,Klebsiella pneumoniae,and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol, 2000, 38:1791-1796.
6Tzelepi E, Giakkoupi P, Sofianou D, et al. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol, 2000,38:542-546.
7Chanal C, Sirot D, Romaszko JP, et al. Survey of extended-spectrum β-lactamases among Enterobacteriaceae. J Antimicrob Chemother, 1996, 38:127-132.
8Coudron PE,Moland ES, Sanders CC. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol, 1997, 35:2593-2597.
9Jevitt LA,Patel JB,Tenover FC,et al.Evaluation of FDA-Approved Disk Dffusion Breackpoint for Daptomycin.2004.ICAAC abstract 48.
